4-Year Multiple Sclerosis Disease Remission After a Single Cycle of Alemtuzumab: a case report
DOI:
https://doi.org/10.34024/rnc.2022.v30.14438Keywords:
Multiple Sclerosis, Alemtuzumab, Disease Modifying Treatment, Case ReportAbstract
Introduction. Alemtuzumab is a humanized monoclonal antibody against the CD52 antigen. It is a highly efficacious drug for the treatment of relapsing remitting multiple sclerosis (MS). The treatment protocol consists in 2 treatment cycles: 12mg/day i.v. infusions for 5 consecutive days and after one-year 12mg/day infusions for 3 days. To our knowledge, there is a single case series in the literature detailing MS remission after a single cycle of Alemtuzumab. Here, we report a similar experience. Case report. A 48-year-old woman with fluctuating right leg weakness for three years and burning pain in the right foot was diagnosed with MS. She was started on Betaferon©. Her condition progressed and in less than one year, she was switched to glatiramer and after new MS relapses to fingolimod. Disease progressed to Expanded Disability Status Scale (EDSS) of 7.0. She was started on Alemtuzumab (five-day course of 12mg i.v. on 6/2018). A second Alemtuzumab cycle was not given since she failed to follow monitoring guidelines. She had no signs of disease activity after four years. Conclusions. It is possible that MS remission may be achieved with a single cycle of Alemtuzumab.
Metrics
References
Devonshire V, Phillips R, Wass H, Roza GD, Senior P. Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations. J Neurol 2018;265:2494-505. https://doi.org/10.1007/s00415-018-8822-y
Borriello G, Lanniello A, Toosy AT. Alopecia Universalis occurring after alemtuzumab treatment for multiple sclerosis. A two-year follow-up of two patients. Int J Environ Res Public Health 2021;18:7338. https://doi.org/10.3390/ijerph18147338
Wang C, Barton J, Kyle K, Ly L, Barnett Y, Hartung HP, et al. Multiple sclerosis: structural and functional integrity of the visual system following alemtuzumab therapy. J Neurol Neurosurg Psychiatry 2021;92:1319-24. https://doi.org/10.1136/jnnp-2021-326164
Kocsik AS, Klein DE, Liedke M, Kaunzner UW, Nealon NM, Gauthier SA, et al. Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS. J Neurol 2018;265:1226-9. https://doi.org/10.1007/s00415-018-8845-4
Soares EF, Basso GME, Gondim FAA. A case report: of 2-year NEDA4 status after a single dose of alemtuzumab. In: Anais do XXVIII Congresso Brasileiro de Neurologia, 2018; São Paulo.
Riera R, Porfírio GJM, Torloni NR, Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group. Alemtuzumab for Multiple Sclerosis. Cochrane Database Syst Rev 2016;2016(4):CD011203. https://doi.org/10.1002/14651858.CD011203.pub2
Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 2019;321:175-87. https://doi.org/10.1001/jama.2018.20588
Marques VD, Passos GR, Mendes MF, Callegaro D, Lana-Peixoto MA, Comini-Frota ER, et al. Brazilian Consensus for the treatment of multiple sclerosis: Brazilian Academy of Neurology and Brazilian Committee on treatment and research in multiple sclerosis. Arq Neuropsiq 2018;76:539-54. https://doi.org/10.1590/0004-282X20180078
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Francisco de Assis Aquino Gondim, Antonio Miguel Furtado Leitão, Eduardo Ferreira Soares, Gabriela Mie Ejima Basso
This work is licensed under a Creative Commons Attribution 4.0 International License.
##plugins.generic.dates.accepted## 2022-11-30
##plugins.generic.dates.published## 2022-12-13